Cargando…

mTOR: A Potential New Target in Nonalcoholic Fatty Liver Disease

The global prevalence of nonalcoholic fatty liver disease (NAFLD) continues to rise, yet effective treatments are lacking due to the complex pathogenesis of this disease. Although recent research has provided evidence for the “multiple strikes” theory, the classic “two strikes” theory has not been o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Feng, Jiayao, Qiu, Shuting, Zhou, Shipeng, Tan, Yue, Bai, Yan, Cao, Hua, Guo, Jiao, Su, Zhengquan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9409235/ https://www.ncbi.nlm.nih.gov/pubmed/36012464 http://dx.doi.org/10.3390/ijms23169196

Ejemplares similares

GOS Ameliorates Nonalcoholic Fatty Liver Disease Induced by High Fat and High Sugar Diet through Lipid Metabolism and Intestinal Microbes
por: Qiu, Shuting, et al.
Publicado: (2022)

Marine Chitooligosaccharide Alters Intestinal Flora Structure and Regulates Hepatic Inflammatory Response to Influence Nonalcoholic Fatty Liver Disease
por: Feng, Jiayao, et al.
Publicado: (2022)

Biodegradation and Prospect of Polysaccharide from Crustaceans
por: Qiu, Shuting, et al.
Publicado: (2022)

Targeting mTOR for cancer therapy
por: Hua, Hui, et al.
Publicado: (2019)

Hepatocellular loss of mTOR aggravates tumor burden in nonalcoholic steatohepatitis-related HCC
por: Kroh, Andreas, et al.
Publicado: (2023)

Empagliflozin activates Sestrin2-mediated AMPK/mTOR pathway and ameliorates lipid accumulation in obesity-related nonalcoholic fatty liver disease
por: Ma, Yuting, et al.
Publicado: (2022)

Mutual interaction between endoplasmic reticulum and mitochondria in nonalcoholic fatty liver disease
por: Wang, Jin, et al.
Publicado: (2020)

Sheng-Jiang Powder Ameliorates High Fat Diet Induced Nonalcoholic Fatty Liver Disease via Inhibiting Activation of Akt/mTOR/S6 Pathway in Rats
por: Li, Juan, et al.
Publicado: (2018)

The mTOR signaling pathway in cardiac aging
por: Dai, Dao-Fu, et al.
Publicado: (2023)

Targeting glutaminase and mTOR
por: Tanaka, Kazuhiro, et al.
Publicado: (2015)

Galacto-Oligosaccharide Alleviates Alcohol-Induced Liver Injury by Inhibiting Oxidative Stress and Inflammation
por: Zhou, Shipeng, et al.
Publicado: (2022)

mTOR Signaling in Cancer and mTOR Inhibitors in Solid Tumor Targeting Therapy
por: Tian, Tian, et al.
Publicado: (2019)

Dehydrovomifoliol Alleviates Nonalcoholic Fatty Liver Disease via the E2F1/AKT/mTOR Axis: Pharmacophore Modeling and Molecular Docking Study
por: Ma, Ji, et al.
Publicado: (2023)

mTOR Pathway and mTOR Inhibitors in Head and Neck Cancer
por: Gao, Wei, et al.
Publicado: (2012)

Myelination and mTOR
por: Figlia, Gianluca, et al.
Publicado: (2017)

mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges
por: Zou, Zhilin, et al.
Publicado: (2020)

Arachidyl amido cholanoic acid improves liver glucose and lipid homeostasis in nonalcoholic steatohepatitis via AMPK and mTOR regulation
por: Fernández-Ramos, David, et al.
Publicado: (2020)

Targeting ganglioneuromas with mTOR inhibitors
por: Tao, Ting, et al.
Publicado: (2021)

mTOR: A Potential Therapeutic Target in Osteoarthritis?
por: Pal, Bandna, et al.
Publicado: (2015)

Phosphorylated Mammalian Target of Rapamycin p-mTOR Is a Favorable Prognostic Factor than mTOR in Gastric Cancer
por: Cao, Guo-dong, et al.
Publicado: (2016)

The Translational Regulation in mTOR Pathway
por: Yang, Miaomiao, et al.
Publicado: (2022)

Cyclopamine and Rapamycin Synergistically Inhibit mTOR Signalling in Mouse Hepatocytes, Revealing an Interaction of Hedgehog and mTor Signalling in the Liver
por: Spormann, Luise, et al.
Publicado: (2020)

Control of mTOR Signaling by Ubiquitin
por: Jiang, Yao, et al.
Publicado: (2019)

The Microstructure, Antibacterial and Antitumor Activities of Chitosan Oligosaccharides and Derivatives
por: Yu, Dawei, et al.
Publicado: (2022)

Kangtaizhi Granule Alleviated Nonalcoholic Fatty Liver Disease in High-Fat Diet-Fed Rats and HepG2 Cells via AMPK/mTOR Signaling Pathway
por: Zhang, Jiaxin, et al.
Publicado: (2020)

Up‐regulation of miR‐497 confers resistance to temozolomide in human glioma cells by targeting mTOR/Bcl‐2
por: Zhu, Danhua, et al.
Publicado: (2017)

Regulation of Osteoclast Growth and Fusion by mTOR/raptor and mTOR/rictor/Akt
por: Tiedemann, Kerstin, et al.
Publicado: (2017)

Escaping mTOR inhibition for cancer therapy: Tumor suppressor functions of mTOR
por: Villar, Victor H., et al.
Publicado: (2017)

Overcoming mTOR Resistance Mutations with a New Generation mTOR Inhibitor
por: Rodrik-Outmezguine, Vanessa S., et al.
Publicado: (2016)

mTOR Signalling in Head and Neck Cancer: Heads Up
por: Tan, Fiona H., et al.
Publicado: (2019)

IDO1 involvement in mTOR pathway: a molecular mechanism of resistance to mTOR targeting in medulloblastoma
por: Folgiero, Valentina, et al.
Publicado: (2016)

Roles of RNA m6A modification in nonalcoholic fatty liver disease
por: Tan, Jian, et al.
Publicado: (2023)

The Role of mTOR Inhibitors in Liver Transplantation: Reviewing the Evidence
por: Klintmalm, Goran B., et al.
Publicado: (2014)

The Upstream Pathway of mTOR-Mediated Autophagy in Liver Diseases
por: Wang, Haojie, et al.
Publicado: (2019)

mTOR and lysosome regulation
por: Puertollano, Rosa
Publicado: (2014)

mTOR, autophagy, and reprogramming
por: Tang, Bor Luen
Publicado: (2014)

mTOR in cerebrovascular disease
por: Van Skike, Candice E., et al.
Publicado: (2019)

mTOR and Tumor Cachexia
por: Duval, Adrian P., et al.
Publicado: (2018)

Double agent mTOR
por: Danzer, Steve C.
Publicado: (2019)

mTOR in Human Diseases
por: Dormond, Olivier
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_7ibuk86h2g7gtcc0q8ajk4rffe